Drug Interaction between Ginseng Extract (GE) and Sorafenib
![]() |
Lee, Nam-Hee
(Department of Pharmacology, Pusan National University School of Korean Medicine)
Park, Ho-Jae (Department of Pharmacology, Pusan National University School of Korean Medicine) Rho, Ja-Sung (Department of Pharmacology, Pusan National University School of Korean Medicine) Kim, Mi-Kyung (National Research and Development Center for Hepatobiliary Diseases, Pusan National University Yangsan Hospital) Lee, Yu-Kyoung (National Research and Development Center for Hepatobiliary Diseases, Pusan National University Yangsan Hospital) Cho, Eun-A (National Research and Development Center for Hepatobiliary Diseases, Pusan National University Yangsan Hospital) Heo, Jeong (Department of Gastroenterology, Pusan National University Hospital) Cho, Mong (Department of Gastroenterology, Pusan National University Yangsan Hospital) Hwang, Tae-Ho (Department of Pharmacology, Pusan National University School of Korean Medicine) |
1 | Zhu, A. X. Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? BMC Med. 42. |
2 | Shin, H. R., J. Y. Kim, T. K. Yun, G. Morgan, and H. Vainio. 2000. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control. 11, 565-576.4. DOI ScienceOn |
3 | Wang, W., Y. Zhao, E. R. Rayburn, D. L. Hill, H. Wang, and R. Zhang. 2007. In vitro anti-cancer activity and structure- activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemoth Pharm. 59, 589-601. DOI ScienceOn |
4 | Wang, X. T., J. L. Martindale, and N. J. Holbrook. 2000. Requirement for erk activation in cisplatin-induced apoptosis. J. Biochem. 275, 9435-39443. |
5 | Wilhelm, S. M., C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, Y. Cao , J. Shujath, S. Gawlak, D. Eveleigh, B. Rowley, L. Liu, L. Adnane, M. Lynch, D. Auclair, I. Taylor, R. Gedrich, A. Voznesensky, B. Riedl, L. E. Post, G. Bollag, and P. A. Trail. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109. DOI ScienceOn |
6 | Woessmann, W., X. B. Chen, and A. Borkhardt. 2002. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemoth Pharm. 50, 397-409. DOI ScienceOn |
7 | Yun, T. K. 2001. Panax ginseng-a non-organ-specific cancer preventive? Lancet Oncol. 2, 49-55. DOI ScienceOn |
8 | Yun, T. K., S. H. Kim, and Y. S. Lee. 1995. Trial of new medium-term model using benzo-(a)pyrene induced lung tumor in newborn mice. Anticancer Res. 15, 839-846. |
9 | Yun, T. K., S. H. Kim, and Y. R. Oh. 1987. Medium-term (nine weeks) method for assay of preventive agents against tumor. J. Korean Cancer Assoc. 1-7. |
10 | Zhang, Z., X. Zhou, H. Shen, D. Wang, and Y Wang. 2009. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 41. |
11 | Heo, J., J. B. Caroline, A. Moon, C. W. Kim, R. Patt, M. K. Kim, Y. K. Lee, S. Y. Oh, H. Y. Woo, K. Parato, J. Rintoul, T. Falls, T. Hickman, B. G. Rhee, J. C. Bell, D. H. Kirn, and T. H. Hwang. 2011. Sequential therapy with JX-594, A targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol. Ther. 19, 1170-1179. DOI ScienceOn |
12 | Koo, H. H., H. J. Jeong, I. Y. Choi, H. J. An, P. D. Moon, S. J. Kim, S. Y. Jee, J. Y. Um, S. H. Hong, S. S. Shin, D. C. Yang, Y. S. Seo, and H. M. Kim. 2007. Mountain grow ginseng induces apoptosis in HL-60 cells and its mechanism have little relation with TNF-alpha production. Am. J. Chinese Med. 35, 169-182. DOI ScienceOn |
13 | Hoshino, R., S. Tanimura, K. Watanabe, T. Kataoka, and M. Kohno. 2001. Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated. J. Biochem. 276, 2686-2692. |
14 | Keating, G. M. and A. Santoro. 2009. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69, 223-240. DOI ScienceOn |
15 | Kim, J. H., J. Y. Oh, B. H. Park, D. E. Lee, J. S. Kim, H. E. Park, M. S. Roh, J. E. Je, J. H. Yoon, S. H. Thorne, D. Kirn, and T. H. Hwang. 2006. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther. 14, 361-370. DOI ScienceOn |
16 | Li, X. L., C. Z. Wang, S. R. Mehendale, S. Sun, Q. Wang, and C. S. Yuan. 2009. Panaxadiol, a puriWed ginseng component, enhances the anti-cancer eVects of 5-Xuorouracil in human colorectal cancer cells. Cancer Chemoth Pharm. 64, 1097-1104. DOI ScienceOn |
17 | Ling, Y., L. Yong, and L. Chang-Xiao. 2006. Metabolism and pharmacokinetics of ginsenosides. Asian J. PD and PK. 6, 103-120. |
18 | Sagar, S. M., D. Yance, and R. K. Wong. 2006. Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Curr. Oncol. 13, 14-26. |
19 | Chao, Z., Y. Shoyama, and T. Hiroyuki. 2006. Pharmacokinetic study of ginsenosides Rb1 and Rg1 in rat by ELISA using anti-ginsenosides Rb1 and Rg1 monoclonal antibodies. Am. J. Chinese Med. 34, 1069-1081. DOI ScienceOn |
20 | Chowdhury, S. J., M. G. Larkin, and M. E. Gore. 2008. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur. J. Cancer 44, 2152-2161. DOI ScienceOn |
21 | Barton, D. L., G. S. Soori, B. A. Bauer, J. A. Sloan, P. A. Johnson, C. Figueras, S. Duane, B. Mattar, H. Liu, P. J. Atherton, B. Christensen, and C. L. Loprinzi. 2010. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatique: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18, 179-187. DOI ScienceOn |
22 | DiGianni, L. M., J. E. Garber, and E. P. Winer. 2002. Complementary and alternative medicine use among women with breast cancer. J. Clin. Oncol. 20, 34S-38S. |
23 | Finn, R. S. 2010. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin. Cancer Res. 16, 390-397. DOI ScienceOn |
24 | Fishbein, A. B., C. Z. Wang, L. X. Li, S. R. Mehendale, S. Sun, H. H. Aung, and C. S. Yuan. 2009. Asian ginseng enhances the anti-proliferative effect of 5-Fluorouracil on human colorectal cancer: comparison between white and red ginseng. Arch. Pharm. Res. 32, 505-513. DOI |
25 | Guida, T., S. Anaganti, L. Provitera, R. Gedrich, E. Sullivan, S. M. Wilhelm, M. Santoro, and F. Carlomagno. 2007. Sorafenib inhibits imatinibresistant KIT and platelet-derived growth factor receptor h gatekeeper mutants. Clin. Cancer Res. 13, 3363-3369. DOI ScienceOn |
26 | Guo, T., N. P. Agaram, G. C. Wong, G. Hom, D. D'Adamo, R. G. Maki, G. K. Schwartz, D. Veach, B. D. Clarkson, S. Singer, R. P. DeMatteo, P. Besmer, and C. R. Antonescu. 2007. Sorafenib inhibits the imatinibresistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 13, 4874-4881. DOI ScienceOn |
27 | Alex, A. A., J. R. Molina, S. J. Mandrekar, R. Marks, J. R. Reid, G. Croghan, L. J. Hanson, J. R. Jett, C. Xia, C. Lathia, and R. Simantov. 2007. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin. Cancer Res. 13, 2684-2691. DOI ScienceOn |
28 | Abou-Alfa, G. K., L. Schwartz, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Greve, J. Y. Douillard, C. Lathia, B. Schwartz, I. Taylor, M. Moscovici, and L. B. Saltz. 2006. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300. DOI ScienceOn |
![]() |